INTERNATIONAL HEADQUARTERS

Grifols Deutschland was established in 1997. Based in Frankfurt, we manage the Biopharma sales in Germany, and Diagnostic sales in the German, Austrian and Swiss (DACH) markets.

We offer a comprehensive portfolio of Grifols products and services. Safety and quality are our top priorities as we deliver on our mission to improve the health and well-being of people around the world.

Industry interactions with the medical profession have a profound and positive influence on patient treatment and on the value of research. As primary providers of healthcare services, both healthcare professionals and healthcare organizations offer us unique, independent insights and expert knowledge on patients' behavior and management of diseases. The ability to gain access to this expertise plays a critical role in informing and guiding industry efforts to improve the quality of patient care and treatment options. And this is why both healthcare professionals and healthcare organizations should be fairly compensated for their contributions, as well as for the services they provide to the industry.

Industry interactions with healthcare professionals and healthcare organizations should not only be conducted with integrity, but also should be transparent. And this is why Grifols Group fully supports, and has voluntarily adopted, the practices reflected in the new EFPIA Code of Practice and will continue to support any other country codes that promulgate transparency reporting.

In this regard, Grifols Deutschland supports transparent documentation of all collaborations with healthcare professionals and organizations and aligns its internal transparency guidelines with those of the EFPIA Code of Practice, FSA (Freiwillige Selbstkontrolle für die Arzneimittelindustrie e. V.) Code and AKG (Arzneimittel und Kooperation im Gesundheitswesen e.V.) Code of Conduct. Based on these guidelines, Grifols Deutschland publishes, within a publicly available list, all its interactions with German-based healthcare professionals and healthcare organizations.

As of 2021 reporting exercise, these interactions are published using the EFPIA disclosure template, which are grouped and split into four categories: (a) Research and Development; (b) Donations; (c) Sponsoring of Educational Events; and (d) Honoraria for Services. Interactions within the category "Research and Development" are published in an aggregate format. In the other categories, interactions are to be published in an individual format, in so far as permitted under German legal requirements on personal data protection.Transparency Germany 2021.

Every day at Grifols, patients inspire our mission to advance the discovery and development of plasma-derived medicines and other innovative biopharmaceutical therapies that improve health and well-being. To further our mission, Grifols Deutschland GmbH actively supports patient organizations, programs and services that promote education, disease awareness and patient advocacy efforts to improve the diagnosis and treatment of disease.